FDA Approves Expanded Indication for KEYTRUDA® (pembrol

FDA Approves Expanded Indication for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Cancer

RAHWAY, N.J.--(BUSINESS WIRE)--Dec 15, 2023--

Related Keywords

Canada , United States , Julie Cunningham , Seagen Padcev , Peter Dannenbaum , Damini Chokshi , Chrissy Trank , Youtube , European Society For Medical Oncology Congress , Patient Support Program , Facebook , Statement Of Merck Co Inc , Pfizer Inc , Agensys Inc , Exchange Commission , Pfizer , Twitter , Merck Access Program , Seagen Inc , Merck Co Inc , Drug Administration , Instagram , Linkedin , Merck Patient Support Program , European Society , Medical Oncology Congress , Presidential Symposium , Time Oncology Review , Bacillus Calmette Guerin , Selected Important Safety , Important Safety Information , Fatal Immune Mediated Adverse , Which Can Present With Diabetic , Nervous System , Connective Tissue , Patients With Multiple , Neck Squamous Cell , Mismatch Repair Deficient , Mismatch Repair Deficient Colorectal , Support Program , Looking Statement , Securities Litigation Reform Act , Annual Report , Prescribing Information , Medication Guide , Media Contacts , Business Wire , Region ,